DANENG LI
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology DUARTE, CA NPI 1285877209
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology CA Acerta Pharma LLC All categories
General Payments — all program years on this page
$512,322.95
- Category: General Payments
- Program years: PY2018–2024
- Record count: 543
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $41,893.61 across 61 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $29,644.00 | 13 |
| Honoraria | $4,950.00 | 2 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,750.00 | 1 |
| Food and Beverage | $1,856.88 | 36 |
| Travel and Lodging | $1,692.73 | 9 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $15,292.61 | 9 |
| Exelixis Inc. | $6,726.26 | 17 |
| EISAI INC. | $4,838.23 | 7 |
| JAZZ PHARMACEUTICALS INC. | $4,340.00 | 2 |
| Coherus Biosciences Inc. | $4,105.50 | 5 |
| ABBVIE INC. | $2,537.50 | 1 |
| AstraZeneca UK Limited | $1,986.50 | 1 |
| Merck Sharp & Dohme Corporation | $1,052.06 | 4 |
| Partner Therapeutics, Inc. | $645.50 | 6 |
| Genentech USA, Inc. | $147.09 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $65.53 | 3 |
| Ipsen Biopharmaceuticals, Inc | $55.10 | 2 |
| TerSera Therapeutics LLC | $39.96 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $34.71 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $27.06 | 1 |
By program year
Records — PY2024 (61)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.